RecruitingNCT06035887

Novel ERG for Detection of Hydroxychloroquine Retinopathy

A Feasibility Study Using Novel, Portable Electroretinography Devices to Detect Hydroxychloroquine Retinopathy

Sponsor

King's College Hospital NHS Trust

Enrollment

140 participants

Start Date

May 31, 2024

Study Type

OBSERVATIONAL

Conditions

Hydroxychloroquine Retinopathy

Summary

The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy. Two devices (the RETEval full-field and flicker ERG and UTAS multifocal ERG) will be evaluated in this study, comparing device outputs to standard of care screening tests, in groups of participants characterised by presence or absence of hydroxychloroquine-related retinopathy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated), Macular Autofluorescence (Standard of Care test), and others for people with hydroxychloroquine retinopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTHand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)

RETEval Complete hand-held electroretinogram

DIAGNOSTIC_TESTTrolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)

UTAS multifocal electroretinogram

DIAGNOSTIC_TESTSpectral-Domain Optical Coherence Tomography (Standard of Care test)

Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)

DIAGNOSTIC_TESTMacular Autofluorescence (Standard of Care test)

Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)

Locations(1)

King's College Hospital

London, London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06035887

Related Trials

Adaptive Optics Imaging of Outer Retinal Diseases

NCT053554152 locations